Royalty Pharma plc (RPRX-Q)
NASDAQ:RPRX
31.17
0.04
(0.13%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
This summary was created by AI, based on 3 opinions in the last 12 months.
Royalty Pharma plc (RPRX) is uniquely positioned in the pharmaceutical industry, holding investments in numerous jointly developed royalty products with major pharma companies. Analysts regard it as a top pick due to its robust financial metrics, including a strong return on equity (ROE) that ranges from 12% to 24% across evaluations. There are indications of significant upside potential with price targets ranging from $33 to $41, suggesting a favorable investment outlook. The company has demonstrated impressive returns on investments, monetizing assets effectively, which has bolstered its ability to pay down debt, engage in share buybacks, and advance product development. Overall, RPRX is viewed as a strong performer in the market with attractive dividend yields and a solid growth trajectory in its portfolio, making it appealing for investors looking for stable income and growth potential.
We reiterate RPRX as a TOP PICK. The company is the largest holder of pharma based royalties, providing late stage funding for forward cash royalties. The company just monetized a recent investment that netted $230 million -- a 76% return on investment -- allowing for a pay down in debt, continuation in share buy backs, and further product development. The company trades at 8x earnings, 1.8x book and supports a ROE of 24%. We recommend trailing up the stop (from $22) to $26, looking to achieve $40 -- upside potential of 25%. Yield 2.6%
RPRX partners with pharma companies like Bristol-Myers to help fund development in exchange for collecting royalties. It pays a good dividend, backed by a payout ratio under 33% of cash flow. It trades at 10x earnings, under 2x book and supports a 17% ROE. Its portfolio grew by 15% this year. We recommend setting a stop-loss at $22, looking to achieve $33 -- upside potential of 28%. Yield 3.2%
(Analysts’ price target is $41.53)- «
- ‹
- 1
- ›
- »
Royalty Pharma plc(RPRX-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Royalty Pharma plc(RPRX-Q) Frequently Asked Questions
What is Royalty Pharma plc stock symbol?
Royalty Pharma plc is a American stock, trading under the symbol RPRX-Q on the NASDAQ (RPRX). It is usually referred to as NASDAQ:RPRX or RPRX-Q
Is Royalty Pharma plc a buy or a sell?
In the last year, there was no coverage of Royalty Pharma plc published on Stockchase.
Is Royalty Pharma plc a good investment or a top pick?
Royalty Pharma plc was recommended as a Top Pick by on . Read the latest stock experts ratings for Royalty Pharma plc.
Why is Royalty Pharma plc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Royalty Pharma plc worth watching?
0 stock analysts on Stockchase covered Royalty Pharma plc In the last year. It is a trending stock that is worth watching.
What is Royalty Pharma plc stock price?
On 2025-04-01, Royalty Pharma plc (RPRX-Q) stock closed at a price of $31.17.
We reiterate RPRX as a TOP PICK. This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development. It trades at 17x earnings, 2.1x book and supports a 12% ROE. We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%. Yield 2.6%
(Analysts’ price target is $41.00)